Objectives: To describe the immunotherapy approaches currently under investigation for the treatment of gliomas. To discuss the management of immune-related adverse effects.
Data sources: Published literature, clinical trials, and oncology association guidance documents.
Conclusion: There are numerous modalities of immune treatment currently being evaluated in patients with glioma, including peptide vaccines, dendritic cell vaccines, oncolytic viruses, CAR-T cells, and checkpoint inhibitor therapy. Immunotherapy utilizes new mechanisms of treatment that may lead us to the eradication of gliomas.
Implications for nursing practice: Immunotherapy is a rapidly growing field in the treatment of gliomas. Oncology nurses are often involved in the safe administration of these therapies, as well as the identification and management of immune-related toxicities.
Keywords: Glioma; Immune-related adverse events; Immunotherapy.
Copyright © 2018. Published by Elsevier Inc.